09 Sep 2019 --- Despite the growing popularity of products containing cannabidiol (CBD), there is still a gap in scientific knowledge on CBD’s real benefits and interaction with other substances. However, this has not put off a large selection of industry players who have engaged with the ingredient in wide-ranging NPD, as well as significant investment in furthering technologies in the space. Yet this sky-rocketing interest has led to increased calls for regulatory clarification – particularly directed toward the US Food and Drug Administration (FDA).
